NCT02879760View on ClinicalTrials.gov

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

February 15, 2020

Study Completion Date

May 24, 2020

Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

Ad-MAGEA3

Intramuscular injection

BIOLOGICAL

MG1-MAGEA3

Intravenous infusion

BIOLOGICAL

Pembrolizumab

Intravenous infusion

Trial Locations (6)

T2N 4N2

Tom Baker Cancer Centre, Calgary

E1C 6Z8

Moncton Hospital, Moncton

L8V 5C2

Juravinski Cancer Centre, Hamilton

K7L 2V7

Kingston General Hospital, Kingston

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

All Listed Sponsors
lead

Turnstone Biologics, Corp.

INDUSTRY

NCT02879760 - Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | Biotech Hunter | Biotech Hunter